TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital

VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company today has started its clinical trial (Phase 2a) in Amyotrophic Lateral Sclerosis (ALS ) at Sahlgrenska University Hospital.

Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “Today, we present an important milestone, with the start of our first phase 2a clinical trial in ALS at Sahlgrenska University Hospital. We are excited and hope ILB’s unique mechanism of action, triggering self-repair and protection will bring new hope to both patients and caregivers suffering from ALS.”

Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “Today there is no cure for ALS and the available drug treatment consists of medicine slowing the progression. We hope our ILB drug will prove to be a game changer in ALS and for those patients and caregivers impacted by this terrible disease.”

The study is performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, an expert in ALS, will be principal investigator.15 patients will be treated with ILB during a 4-week period.

Share on facebook
Share on twitter
Share on linkedin
Share on email